Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

EUROPEAN UNION, JUL 25 – ZURZUVAE, a novel 14-day oral treatment, showed symptom improvement by day three in clinical trials, addressing postpartum depression affecting up to 20% of European women, CHMP said.

Summary by Globe Newswire
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the...

7 Articles

Globe NewswireGlobe Newswire
+5 Reposted by 5 other sources
Center

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the...

Read Full Article
MedscapeMedscape

EMA OKs Oral Treatment for Postnatal Depression

The pill can reduce symptoms within 2 weeks' treatment.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources lean Left
67% Left

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Inside Halton broke the news in Halton Hills, Canada on Friday, July 25, 2025.
Sources are mostly out of (0)

Similar News Topics

Opinion icon

Opinion

Health icon

Health

Business icon

Business

Medical icon

Medical

European Union icon

European Union

Cambridge, Massachusetts icon

Cambridge, Massachusetts

News
For You
SearchBlindspotLocal